Radiotherapy

Radiation therapy directed at the primary prostate tumor decreased mortality risk by 31% in adjusted analyses, a study found.

In a small phase 2 trial involving men with intermediate-risk prostate cancer, a single ultra-high dose of radiation was safe and comparable to curative hypofractionated stereotactic body radiation therapy in tumor control and quality-of-life measures.

The overall and failure-free survival benefit of adding prostate radiation therapy to standard of care for metastatic prostate cancer declines with increasing number of bone metastases, a study found.

A randomized phase 3 trial demonstrated that whole-pelvic radiation therapy was associated with improved biochemical failure-free and disease-free survival compared with prostate-only radiation in patients with high-risk and very high-risk prostate cancer.

Patients with node-positive prostate cancer have a 22% increased risk for death if they receive external beam radiation therapy at facilities that handle a relatively low volume of prostate radiation cases, a study found.